Novavax 거래 NVAX

매도
 매수

Novavax 실시간 차트

5m 15m 30m 1h 4h 1d 1w

상품 기초

Weekly Search
Weekly
Daily
날짜 종료 변경 변동(%) 열기 높음 낮음

Novavax news

2021 5월 11, 13:20

US pre-market: selling unabated

2021 5월 06, 08:27

Stocks rally as Fed speakers get back on script, earnings support + Bank of England set to raise forecasts

2021 Feb 28, 07:36

Week Ahead: RBA speaks, US NFPs released & OPEC clash

2020 5월 26, 08:04

Leg up: stocks make new ground, travel stocks soar

최신 뉴스

더 보기
Ava Grace 2025 Oct 25, 00:00

Trump's Sudden Russia Policy Shift: Rubio's Influence and Implications

Emma Rose 2025 Oct 25, 00:00

Global Market Review: Gold Volatility and Tech Stock Surge Amidst Economic Uncertainty

Noah Lee 2025 Oct 25, 00:00

September CPI Data: Inflation Hurdles, Tariff Impacts, and Fed Rate Cut Expectations

Emma Rose 2025 Oct 25, 00:00

Navigating the AI Boom: Strategies for Investors Amid Nvidia's Valuation Surge

Sophia Claire 2025 Oct 25, 00:00

Fund Managers Cautious in Q4: AI, Inflation, and Monetary Policy in Focus

Emma Rose 2025 Oct 25, 00:00

US Government Shutdown Threatens October Inflation Data Release

Sophia Claire 2025 Oct 24, 00:00

US-EU Relations: Russia Sanctions Unite Despite Trade Tensions

Emma Rose 2025 Oct 24, 00:00

BOJ Warns of Japan Stock Market Overheating, U.S. Trade Policy Risk

정보

스프레드

0.07

스프레드(%)

0.8226 %

레버리지

1:10

익일 이자 매수

-0.0597 %

익일 이자 매도

-0.0292 %

통화

USD

거래 시간

시장 폐장

월요일

13:31 - 19:59

화요일

13:31-19:59

수요일

13:31-19:59

목요일

13:31-19:59

금요일

13:31-19:59

분석 및 통계

열기

---

이전 종가

---

52주 최고/최저

--- – ---

시가총액

1383832576

발행 주식 수

162421645

수익 날짜 (다음)

2019-05-10

배당수익률

2019-05-10

배당락일

예상 연간 배당금

0

예상 연간 배당수익률

0

EPS

2.26

이 상품에 대해 자세히 알아보기

Novavax Novavax Inc
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

관련 상품

자산
매도
매수
변동(%)

지금 거래하기

지금 거래하기

지금 거래하기

지금 거래하기
view_all_instruments

latest_education_articles

더 보기
Trustpilot